Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

Also called NCT01451398

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 353 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01451398
Other papers using this trial's data
  • Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents Diabetes care, 2015-12 DOI, PubMed 26253730

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01451398. Randomized; double masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-06 (actual). Results posted on 2014-10-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
Intervention (Drug)
Technosphere® Insulin
Intervention (Drug)
Technosphere Powder
Lead sponsor
Mannkind Corporation (class: industry)

Record details

Record id
cardio:ct-nct01451398
Content hash
4c105e0fa4bc24b22e68d2e7c69a1004171851909c88d9d18bf29e4cd45ff9ea